Methotrexate in psoriatic arthritis

Joint Bone Spine

Volumn 81, Issue 2, 2014, Pages 107-109

  Pertuiset, Edouard ^a  

^a CENTRE HOSPITALIER RENÉ DUBOS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

DISEASE COURSE; DRUG EFFICACY; EDITORIAL; HUMAN; INTENTION TO TREAT ANALYSIS; PSORIATIC ARTHRITIS; DISEASE ACTIVITY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; JOINT SWELLING; LOW DRUG DOSE; PAIN; SYNOVITIS;

METHOTREXATE; PSORIATIC ARTHRITIS; SPONDYLOARTHROPATHIES; TREATMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; METHOTREXATE;

EID: 84898549001     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.10.005     Document Type: Editorial

References (26)

1. Gladman D.D. Psoriatic arthritis. Kelley's textbook of Rheumatology 2005, Volume II:1155-1164. Elsevier Saunders. Seventh Edition.
2. Dougados M., Landewé R. Spondyloarthritides: pathogenesis, clinical aspects and diagnosis. Eular Compendium on Rheumatic Diseases 2009, 92-115. BMJ Publishing Group and EULAR. J.W.L. Bijlsma (Ed.).
3. Smolen J.S., Landewé R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
4. Schmitt J., Zhang Z., Wozel G., et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008, 159:513-526.
5. Haibel H., Brandt H.C., Song I.H., et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007, 66:419-421.
6. Sieper J., Haibel H., Mielants H. Management of spondyloarthritides. Eular Compendium on rheumatic diseases 2009, 116-131. BMJ Publishing Group and EULAR. J.W.L. Bijlsma (Ed.).
7. Ravindran V., Scott D.L., Choy E.H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008, 67:855-859.
8. Ritchlin C.T., Kavanaugh A., Gladman D.D., et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68:1387-1394.
9. Pham T., Fautrel B., Dernis E., et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007, 74:638-646.
10. Dernis E., Lavie F., Salliot C., Flipo R.M., et al. Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine 2009, 76:524-531.
11. Ash Z., Gaujoux-Viala C., Gossec L., et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012, 71:319-326.
12. Kingsley G.H., Kowalczyk A., Taylor H., et al. A randomized placebo-controlled trial of MTX in PsA. Rheumatology 2012, 51:1368-1377.
13. Dougados M. Methotrexate in peripheral spondyloarthritis including psoriatic arthritis: a need for further evaluation. Rheumatology 2012, 51:1343-1344.
14. Black R.L., O'Brien W.M., Van Scott E.J., et al. Methotrexate therapy in psoriatic arthritis. Double-blind study on 21patients. J Am Med Assoc 1964, 189:743-747.
15. Willkens R.F., Williams H.J., Ward J.R., et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984, 27:376-381.
16. Scarpa R., Peluso R., Atteno M., et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 2008, 27:823-826.
17. Spadaro A., Riccieri V., Sili-Scavalli A., et al. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995, 13:589-593.
18. Mease P. Update on treatment of psoriatic arthritis. Bull NYU Hosp Jt Dis 2012, 70:167-171.
19. Baranauskaite A., Raffayova H., Kungurov N.V., et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012, 71:541-548.
20. Lie E., van der Heijde D., Uhlig T., et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010, 69:671-676.
21. Mease P.J., Kivitz A.J., Burch F.X., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
22. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289.
23. Glintborg B., Østergaard M., Dreyer L., et al. Treatment response, drug survival, and predictors thereof in 764patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011, 63:382-390.
24. Fagerli K.M., Lie E., van der Heijde D., et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440patients included in the NOR-DMARD study. Ann Rheum Dis 2014, 73:132-137.
25. Eder L., Thavaneswaran A., Chandran V., et al. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis 2013, [Epub ahead of print].
26. Finzel S., Kraus S., Schmidt S., et al. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors. Ann Rheum Dis 2013, 72:1176-1181.